{"DataElement":{"publicId":"6738976","version":"1","preferredName":"Disease Response International Myeloma Working Group Minimal Residual Disease Criteria Category","preferredDefinition":"Categorization of response to treatment for minimal residual disease (MRD) based on criteria created by the International Myeloma Working Group (IMWG).","longName":"RESP_IMWG_MRD_CAT","context":"CCR","contextVersion":"1","DataElementConcept":{"publicId":"6738968","version":"1","preferredName":"Disease Response International Myeloma Working Group Minimal Residual Disease Criteria","preferredDefinition":"The pathologic and/or clinical changes that result from treatment. The changes may include eradication of detectable disease, stabilization of disease, or disease progression._Uniform consensus criteria created by the International Myeloma Working Group to describe response to treatment for minimal residual disease.","longName":"2607696v1.0:6738966v1.0","context":"CCR","contextVersion":"1","ObjectClass":{"publicId":"2607696","version":"1","preferredName":"Response","preferredDefinition":"In medicine, an improvement related to treatment.","longName":"C50995","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Disease Response","conceptCode":"C50995","definition":"The pathologic and/or clinical changes that result from treatment. The changes may include eradication of detectable disease, stabilization of disease, or disease progression.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"2AF31F79-4CA1-08D3-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-03-05","endDate":null,"createdBy":"UMLLOADER_CTOM","dateCreated":"2007-03-05","modifiedBy":"SBREXT","dateModified":"2007-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"6738966","version":"1","preferredName":"International Myeloma Working Group Minimal Residual Disease Criteria","preferredDefinition":"Uniform consensus criteria created by the International Myeloma Working Group to describe response to treatment for minimal residual disease.","longName":"C159799","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"International Myeloma Working Group Minimal Residual Disease Criteria","conceptCode":"C159799","definition":"Uniform consensus criteria created by the International Myeloma Working Group to describe response to treatment for minimal residual disease.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"87C51500-6888-1163-E053-F662850A12AB","latestVersionIndicator":"Yes","beginDate":"2019-04-30","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-04-30","modifiedBy":"ONEDATA","dateModified":"2019-04-30","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008550","version":"1","preferredName":"Disease Response","preferredDefinition":"the response criteria (includes RECIST and others) and associated documentation of disease.","longName":"DZ_RESP","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22C0651-216B-5273-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"CCR:Center for Cancer Research","workflowStatus":"RELEASED","registrationStatus":"Application","id":"87C51500-6899-1163-E053-F662850A12AB","latestVersionIndicator":"Yes","beginDate":"2019-04-30","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-04-30","modifiedBy":"COOPERM","dateModified":"2019-05-01","changeDescription":"Created for NCI-INC0371350-19C0078 IMWG curation 4.19.19 mc","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"6738943","version":"1","preferredName":"IMWG MRD Category","preferredDefinition":"A grouping of items based on some commonality or by user defined characteristics.","longName":"IMWG_MRD_CAT","context":"CCR","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"50","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Imaging plus MRD-negative (Img MRDnegCR)","valueDescription":"IMWG Imaging plus MRD-negative","ValueMeaning":{"publicId":"6738944","version":"1","preferredName":"IMWG Imaging plus MRD-negative","longName":"6738944","preferredDefinition":"Minimal residual disease negativity as defined by next-generation flow cytometry or next-generation sequencing plus disappearance of every area of increased tracer uptake found at baseline or a preceding PET/CT or decrease to less mediastinal blood pool standard uptake value or decrease to less than that of surrounding normal tissue.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"IMWG Imaging plus MRD-negative","conceptCode":"C159803","definition":"Minimal residual disease negativity as defined by next-generation flow cytometry or next-generation sequencing plus disappearance of every area of increased tracer uptake found at baseline or a preceding PET/CT or decrease to less mediastinal blood pool standard uptake value or decrease to less than that of surrounding normal tissue.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"87C3C814-82F6-5905-E053-F662850A936A","latestVersionIndicator":"Yes","beginDate":"2019-04-30","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-04-30","modifiedBy":"ONEDATA","dateModified":"2019-04-30","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"87C3C814-830F-5905-E053-F662850A936A","beginDate":"2019-04-30","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-04-30","modifiedBy":"ONEDATA","dateModified":"2019-04-30","deletedIndicator":"No"},{"value":"Sequencing MRD-negative (Seq MRDnegCR)","valueDescription":"IMWG Sequencing MRD-negative","ValueMeaning":{"publicId":"6738945","version":"1","preferredName":"IMWG Sequencing MRD-negative","longName":"6738945","preferredDefinition":"Absence of clonal plasma cells by next-generation sequencing on bone marrow aspirate in which presence of a clone is defined as less than two identical sequencing reads obtained after DNA sequencing of bone marrow aspirates using the LymphoSIGHT platform (or validated equivalent method) with a minimum sensitivity of 1 in 10^5 nucleated cells or higher.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"IMWG Sequencing MRD-negative","conceptCode":"C159802","definition":"Absence of clonal plasma cells by next-generation sequencing on bone marrow aspirate in which presence of a clone is defined as less than two identical sequencing reads obtained after DNA sequencing of bone marrow aspirates using the LymphoSIGHT platform (or validated equivalent method) with a minimum sensitivity of 1 in 10^5 nucleated cells or higher.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"87C3C814-831B-5905-E053-F662850A936A","latestVersionIndicator":"Yes","beginDate":"2019-04-30","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-04-30","modifiedBy":"ONEDATA","dateModified":"2019-04-30","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"87C3C814-8334-5905-E053-F662850A936A","beginDate":"2019-04-30","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-04-30","modifiedBy":"ONEDATA","dateModified":"2019-04-30","deletedIndicator":"No"},{"value":"Flow MRD-negative (Flow MRDnegCR)","valueDescription":"IMWG Flow MRD-negative","ValueMeaning":{"publicId":"6738946","version":"1","preferredName":"IMWG Flow MRD-negative","longName":"6738946","preferredDefinition":"Absence of phenotypically aberrant clonal plasma cells by next-generation flow cytometry on bone marrow aspirates using the EuroFlow standard operation procedure for minimal residual disease detection in multiple myeloma (or validated equivalent method) with a minimum sensitivity of 1 in 10^5 nucleated cells or higher.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"IMWG Flow MRD-negative","conceptCode":"C159801","definition":"Absence of phenotypically aberrant clonal plasma cells by next-generation flow cytometry on bone marrow aspirates using the EuroFlow standard operation procedure for minimal residual disease detection in multiple myeloma (or validated equivalent method) with a minimum sensitivity of 1 in 10^5 nucleated cells or higher.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"87C3C814-8340-5905-E053-F662850A936A","latestVersionIndicator":"Yes","beginDate":"2019-04-30","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-04-30","modifiedBy":"ONEDATA","dateModified":"2019-04-30","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"87C3C814-8359-5905-E053-F662850A936A","beginDate":"2019-04-30","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-04-30","modifiedBy":"ONEDATA","dateModified":"2019-04-30","deletedIndicator":"No"},{"value":"Sustained MRD-negative (Sustained MRDnegCR)","valueDescription":"IMWG Sustained MRD-negative","ValueMeaning":{"publicId":"6738947","version":"1","preferredName":"IMWG Sustained MRD-negative","longName":"6738947","preferredDefinition":"Minimal residual disease negativity in the marrow, by next-generation flow cytometry or next-generation sequencing, or both, and by imaging, confirmed a minimum of 1 year apart.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"IMWG Sustained MRD-negative","conceptCode":"C159800","definition":"Minimal residual disease negativity in the marrow, by next-generation flow cytometry or next-generation sequencing, or both, and by imaging, confirmed a minimum of 1 year apart.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"87C3C814-8365-5905-E053-F662850A936A","latestVersionIndicator":"Yes","beginDate":"2019-04-30","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-04-30","modifiedBy":"ONEDATA","dateModified":"2019-04-30","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"87C3C814-837E-5905-E053-F662850A936A","beginDate":"2019-04-30","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-04-30","modifiedBy":"ONEDATA","dateModified":"2019-04-30","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008550","version":"1","preferredName":"Disease Response","preferredDefinition":"the response criteria (includes RECIST and others) and associated documentation of disease.","longName":"DZ_RESP","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22C0651-216B-5273-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2433877","version":"1","preferredName":"Category","preferredDefinition":"Category; used informally to mean a class of things.","longName":"C25372","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Category","conceptCode":"C25372","definition":"A grouping of items based on some commonality or by user defined characteristics.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"062E16DD-4D2F-16F1-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-11-28","endDate":null,"createdBy":"ALAIS","dateCreated":"2005-11-28","modifiedBy":"ONEDATA","dateModified":"2005-11-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"CCR:Center for Cancer Research","workflowStatus":"RELEASED","registrationStatus":"Application","id":"87C3C814-82DE-5905-E053-F662850A936A","latestVersionIndicator":"Yes","beginDate":"2019-04-30","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-04-30","modifiedBy":"COOPERM","dateModified":"2019-05-01","changeDescription":"Created for NCI-INC0371350-19C0078 IMWG curation 4.19.19 mc","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2008601","version":"1","longName":"C3D Domain","context":"CCR","ClassificationSchemeItems":[{"publicId":"2811685","version":"1","longName":"CCR","context":"CCR"}]},{"publicId":"2182125","version":"1","longName":"CCR Implementation","context":"CCR","ClassificationSchemeItems":[{"publicId":"2811673","version":"1","longName":"C3D","context":"CCR"}]}],"AlternateNames":[],"ReferenceDocuments":[{"name":"IMWG MRD Response Criteria","type":"Preferred Question Text","description":"IMWG MRD Response Criteria","url":null,"context":"CCR"}],"origin":"CCR:Center for Cancer Research","workflowStatus":"RELEASED","registrationStatus":"Application","id":"87C4DBE6-6741-3B8F-E053-F662850A164D","latestVersionIndicator":"Yes","beginDate":"2019-04-30","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-04-30","modifiedBy":"COOPERM","dateModified":"2019-05-01","changeDescription":"Created for NCI-INC0371350-19C0078 IMWG curation 4.19.19 mc","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}